Derek DiRocco, PhD

Derek DiRocco is a Partner at RA Capital Management. Based on RA Capital’s official team page, he works on both public and private investments and serves as a board director for companies including Acrivon, Bambusa Therapeutics, Evommune, Forward Therapeutics, Frontier Medicines, Mineralys, Rivus, Stipple Bio, and Syntelios. His prior investment landscape coverage included solid tumor oncology. Before investing, he completed postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School focused on Wnt signaling in mouse models of kidney disease and research related to solid organ fibrosis. He holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington.